LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and patient communication,” explains Dr. Singhi.
All content for Lung Cancer Rx is the property of Oncology News Central and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and patient communication,” explains Dr. Singhi.
“Absolute Flood” of ADCs and Key Data Lead to “Good Challenges” in EGFR-Mutated NSCLC
Lung Cancer Rx
30 minutes
1 week ago
“Absolute Flood” of ADCs and Key Data Lead to “Good Challenges” in EGFR-Mutated NSCLC
In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation.
“I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cancer Institute in Boston. Dr. Rotow explains how key data from the HARMONi, COMPEL, and MARIPOSA-2 studies and a wave of new treatment options on the horizon have led to “good challenges” in non-small cell lung cancer care.
Lung Cancer Rx
LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and patient communication,” explains Dr. Singhi.
